Merit Medical Systems (MMSI) Stock Overview
Designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for MMSI from our risk checks.
MMSI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Merit Medical Systems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$60.44 |
| 52 Week High | US$100.19 |
| 52 Week Low | US$60.80 |
| Beta | 0.58 |
| 1 Month Change | -10.72% |
| 3 Month Change | -23.85% |
| 1 Year Change | -34.92% |
| 3 Year Change | -28.56% |
| 5 Year Change | -2.18% |
| Change since IPO | 1,065.86% |
Recent News & Updates
Merit Medical Systems: Creating More Growth Engines (Rating Upgrade)
May 02
Tariffs And OEM Volatility Will Pressure Margins Yet Long Term Procedure Demand Will Support Progress
Catalysts About Merit Medical Systems Merit Medical Systems develops and sells medical devices used in vascular, oncology, cardiac, renal and endoscopy procedures worldwide. What are the underlying business or industry changes driving this perspective?
MMSI: 2026 Guidance Execution And Margin Resilience Will Drive Future Upside
Analysts have nudged their price targets on Merit Medical slightly lower, with the updated fair value estimate moving from about $101.18 to $98.36 as they factor in modestly softer profit margin assumptions and a somewhat higher future P/E multiple, alongside recent target cuts and a downgrade tied to 2026 guidance uncertainty. Analyst Commentary Recent research on Merit Medical Systems highlights a mix of confidence in the business model and caution around execution against medium term targets, especially the 2026 outlook.Recent updates
Merit Medical Systems: Creating More Growth Engines (Rating Upgrade)
May 02Tariffs And OEM Volatility Will Pressure Margins Yet Long Term Procedure Demand Will Support Progress
Catalysts About Merit Medical Systems Merit Medical Systems develops and sells medical devices used in vascular, oncology, cardiac, renal and endoscopy procedures worldwide. What are the underlying business or industry changes driving this perspective?MMSI: 2026 Guidance Execution And Margin Resilience Will Drive Future Upside
Analysts have nudged their price targets on Merit Medical slightly lower, with the updated fair value estimate moving from about $101.18 to $98.36 as they factor in modestly softer profit margin assumptions and a somewhat higher future P/E multiple, alongside recent target cuts and a downgrade tied to 2026 guidance uncertainty. Analyst Commentary Recent research on Merit Medical Systems highlights a mix of confidence in the business model and caution around execution against medium term targets, especially the 2026 outlook.MMSI: 2026 Margin Outlook And Guidance Will Drive Upside Potential
Analysts have trimmed the blended fair value estimate for Merit Medical Systems to about $101 from roughly $104, reflecting a lower projected price target that incorporates higher discount rates, slightly softer revenue growth assumptions, and a more moderate future P/E multiple, even as margin expectations improve. Analyst Commentary Recent Street research on Merit Medical Systems presents a mixed picture, with some analysts trimming targets or ratings on guidance uncertainty, while others still see room for valuation support based on execution and margins.We Like These Underlying Return On Capital Trends At Merit Medical Systems (NASDAQ:MMSI)
Dec 31
Calculating The Fair Value Of Merit Medical Systems, Inc. (NASDAQ:MMSI)
Jul 14If EPS Growth Is Important To You, Merit Medical Systems (NASDAQ:MMSI) Presents An Opportunity
Jun 29Risks To Shareholder Returns Are Elevated At These Prices For Merit Medical Systems, Inc. (NASDAQ:MMSI)
May 21We Take A Look At Why Merit Medical Systems, Inc.'s (NASDAQ:MMSI) CEO Has Earned Their Pay Packet
May 07Merit Medical Systems' (NASDAQ:MMSI) Returns On Capital Are Heading Higher
Apr 11Is Now An Opportune Moment To Examine Merit Medical Systems, Inc. (NASDAQ:MMSI)?
Mar 30Here's Why We Think Merit Medical Systems (NASDAQ:MMSI) Is Well Worth Watching
Mar 18Merit Medical: A Success Story That Keeps Getting Better
Mar 16A Look At The Fair Value Of Merit Medical Systems, Inc. (NASDAQ:MMSI)
Mar 06Merit Medical Systems (NASDAQ:MMSI) Seems To Use Debt Rather Sparingly
Feb 10Why We're Not Concerned About Merit Medical Systems, Inc.'s (NASDAQ:MMSI) Share Price
Jan 17Merit Medical Systems: Solid Execution, Stretched Valuations
Jan 08Returns Are Gaining Momentum At Merit Medical Systems (NASDAQ:MMSI)
Dec 23Is Now An Opportune Moment To Examine Merit Medical Systems, Inc. (NASDAQ:MMSI)?
Dec 11Is Now The Time To Put Merit Medical Systems (NASDAQ:MMSI) On Your Watchlist?
Nov 29Merit Medical Systems, Inc. (NASDAQ:MMSI) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Nov 02Is Merit Medical Systems (NASDAQ:MMSI) A Risky Investment?
Nov 01Merit Medical Systems - Impressive Momentum
Sep 17The Price Is Right For Merit Medical Systems, Inc. (NASDAQ:MMSI)
Sep 17Why Merit Medical Systems, Inc. (NASDAQ:MMSI) Could Be Worth Watching
Sep 04
China Market And New Products Propel Medical Equipment Giant To New Heights
Enhanced international market performance, notably in China, hints at potential market share and revenue increases.Merit Medical Systems (NASDAQ:MMSI) Is Doing The Right Things To Multiply Its Share Price
Aug 22These 4 Measures Indicate That Merit Medical Systems (NASDAQ:MMSI) Is Using Debt Safely
Jul 31Shareholder Returns
| MMSI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -9.4% | -5.0% | 0.6% |
| 1Y | -34.9% | -19.0% | 28.4% |
Return vs Industry: MMSI underperformed the US Medical Equipment industry which returned -19% over the past year.
Return vs Market: MMSI underperformed the US Market which returned 28.4% over the past year.
Price Volatility
| MMSI volatility | |
|---|---|
| MMSI Average Weekly Movement | 4.9% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MMSI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MMSI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 7,500 | Martha Aronson | www.merit.com |
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology products, such as soft tissue biopsy products and accessories; cardiac intervention products consisting of cardiac access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention products; and spine products, including vertebral augmentation, radiofrequency ablation, and bone biopsy systems.
Merit Medical Systems, Inc. Fundamentals Summary
| MMSI fundamental statistics | |
|---|---|
| Market cap | US$3.70b |
| Earnings (TTM) | US$139.34m |
| Revenue (TTM) | US$1.54b |
Is MMSI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MMSI income statement (TTM) | |
|---|---|
| Revenue | US$1.54b |
| Cost of Revenue | US$791.39m |
| Gross Profit | US$751.05m |
| Other Expenses | US$611.71m |
| Earnings | US$139.34m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.34 |
| Gross Margin | 48.69% |
| Net Profit Margin | 9.03% |
| Debt/Equity Ratio | 45.2% |
How did MMSI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/05 22:38 |
| End of Day Share Price | 2026/05/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Merit Medical Systems, Inc. is covered by 23 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Baird |
| David Rescott | Baird |
| Michael Petusky | Barrington Research Associates, Inc. |